TRM: Human Pancreatic Ductal Adendocarcinoma (PDAC) Derived Cell Lines 779e and 1334

Technology Description

Two Human Pancreatic Ductal Adendocarcinoma (PDAC) Derived Cell Lines have been developed and authenticated by validating mutations in the KRas gene and by assessing the histology of tumors derived from xenografted lines.

779e- established from a moderate-to-poorly differentiated patient derived tumor that harbored KRasG12Fmutation.

1334-established from a PDAC patient liver metastasis and harbors KRasG12D mutation.

Applications

The cell lines are suitable for use experimental use in understanding the signaling pathways involved in the regulation of PDA.

Intellectual Property Info

This represents tangible research material which is available by a material transfer agreement (MTA) to an academic institution or a bailment license agreement (for-profit company).

Related Materials

• Scully KM, Lahmy R, Signaevskaia L, Sasik R, Medal R, Kim H, French R, James B, Wu Y, Lowy AM, Itkin-Ansari P. E47 Governs the MYC-CDKN1B/p27KIP1-RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16INK4A and Wild-Type p53. Cell Mol Gastroenterol Hepatol. 2018 May 16;6(2):181-198. doi: 10.1016/j.jcmgh.2018.05.002. eCollection 2018. - 05/16/2018
• Villarino N, Signaevskaia L, van Niekerk J, Medal R, Kim H, Lahmy R, Scully K, Pinkerton A, Kim S, Lowy A, Itkin-Ansari P. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget. 2017 Jun 21;8(32):53154-53167. doi: 10.18632/oncotarget.18587. eCollection 2017 Aug 8. - 08/08/2017